Polyphosphates form antigenic complexes with platelet factor 4 (PF4) and enhance PF4-binding to bacteria

Thrombosis and Haemostasis

Volumn 114, Issue 6, 2015, Pages 1189-1198

  Brandt, Sven ^a   Krauel, Krystin ^b   Jaax, Miriam ^b   Renné, Thomas ^c,d   Helm, Christiane A ^e   Hammerschmidt, Sven ^f   Delcea, Mihaela ^a   Greinacher, Andreas ^b  

^a ZIK HIKE Centre of innovation competence Humoral Immune Reactions in Cardiovascular Diseases   (Germany)

^b Institute for Immunology and Transfusion Medicine   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d KAROLINSKA INSTITUTE   (Sweden)

^e Institute for Experimental Physics   (Germany)

^f Interfaculty Institute for Genetics and Functional Genomics   (Germany)

Author keywords

Antigen generation; Conformational changes; Phagocytosis; Platelet factor 4; Polyphosphates

Indexed keywords

POLYPHOSPHATE; THROMBOCYTE FACTOR 4; ANTIGEN; HEPARIN; PROTEIN BINDING;

ARTICLE; BACTERIUM ADHERENCE; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; ESCHERICHIA COLI; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HUMAN CELL; INNATE IMMUNITY; ISOTHERMAL TITRATION CALORIMETRY; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; CALORIMETRY; CHEMISTRY; COMPARATIVE STUDY; CROSS REACTION; DOSE RESPONSE; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; PROTEIN SECONDARY STRUCTURE;

ANTIGENS; CALORIMETRY; CIRCULAR DICHROISM; CROSS REACTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI; HEPARIN; HUMANS; IMMUNITY, INNATE; NEUTROPHILS; PHAGOCYTOSIS; PLATELET FACTOR 4; POLYPHOSPHATES; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY;

EID: 84983112914     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-01-0062     Document Type: Article

References (60)

1. Achbergerova L, Nahalka J. Polyphosphate-an ancient energy source and active metabolic regulator. Microb Cell Factories 2011; 10: 63.
2. Gray MJ, Wholey WY, Wagner NO, et al. Polyphosphate is a primordial chaperone. Mol Cell 2014; 53: 689-699.
3. Rao NN, Gomez-Garcia MR, Kornberg A. Inorganic polyphosphate: essential for growth and survival. Annu Rev Biochem 2009; 78: 605-647.
4. Ruiz FA, Lea CR, Oldfield E, et al. Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes. J Biol Chem 2004; 279: 44250-44257.
5. Herzberg MC, Krishnan LK, Macfarlane GD. Involvement of Alpha(2)-Adrenoceptors and G-Proteins in the Modulation of Platelet Secretion in Response to Streptococcus-Sanguis. Crit Rev Oral Biol M 1993; 4: 435-442.
6. Muller F, Mutch NJ, Schenk WA, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009; 139: 1143-1156.
7. Moreno-Sanchez D, Hernandez-Ruiz L, Ruiz FA, et al. Polyphosphate Is a Novel Pro-inflammatory Regulator of Mast Cells and Is Located in Acidocalcisomes. J Biol Chem 2012; 287: 28435-28444.
8. Kornberg A, Rao NN, Ault-Riche D. Inorganic polyphosphate: A molecule of many functions. Annu Rev Biochem 1999; 68: 89-125.
9. Morrissey JH. Polyphosphate: a link between platelets, coagulation and inflammation. Intern J Hematol 2012; 95: 346-352.
10. Morrissey JH, Choi SH, Smith SA. Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation. Blood 2012; 119: 5972-5979.
11. Smith SA, Mutch NJ, Baskar D, et al. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci USA 2006; 103: 903-908.
12. Smith SA, Choi SH, Davis-Harrison R, et al. Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood 2010; 116: 4353-4359.
13. Smith SA, Morrissey JH. Polyphosphate enhances fibrin clot structure. Blood 2008; 112: 2810-2816.
14. Mutch NJ, Engel R, de Willige SU, et al. Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin. Blood 2010; 115: 3980-3988.
15. Choi SH, Smith SA, Morrissey JH. Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood 2011; 118: 6963-6970.
16. Wat JM, Foley JH, Krisinger MJ, et al. Polyphosphate suppresses complement via the terminal pathway. Blood 2014; 123: 768-776.
17. Nickel KF, Spronk HM, Mutch NJ, et al. Time-dependent degradation and tissue factor addition mask the ability of platelet polyphosphates in activating factor XII-mediated coagulation. Blood 2013; 122: 3847-3849.
18. Lorenz B, Leuck J, Kohl D, et al. Anti-HIV-1 activity of inorganic polyphosphates. J Acq Immune Def Syndr Human Retrovirol 1997; 14: 110-118.
19. Smith SA, Morrissey JH. Polyphosphate as a general procoagulant agent. J Thromb Haemost 2008; 6: 1750-1756.
20. Smith SA, Choi SH, Collins JNR, et al. Inhibition of polyphosphate as a novel strategy for preventing thrombosis and inflammation. Blood 2012; 120: 5103-5110.
21. Wolpe SD, Cerami A. Macrophage Inflammatory Protein-1 and Protein-2-Members of a Novel Superfamily of Cytokines. Faseb J 1989; 3: 2565-2573.
22. Huang SS, Huang JS, Deuel TF. Proteoglycan Carrier of Human-Platelet Factor-4-Isolation and Characterization. J Biol Chem 1982; 257: 1546-1550.
23. Deuel TF, Keim PS, Farmer M, et al. Amino-Acid Sequence of Human Platelet Factor 4. Proc Natl Acad Sci USA 1977; 74: 2256-2258.
24. Rucinski B, Niewiarowski S, James P, et al. Antiheparin Proteins Secreted by Human Platelets-Purification, Characterization, and Radioimmunoassay. Blood 1979; 53: 47-62.
25. Kaplan KL, Broekman MJ, Chernoff A, et al. Platelet Alpha-Granule Proteins-Studies on Release and Subcellular-Localization. Blood 1979; 53: 604-618.
26. Brandt S, Krauel K, Gottschalk KE, et al. Characterisation of the conformational changes in platelet factor 4 induced by polyanions: towards in vitro prediction of antigenicity. Thromb Haemost 2014; 112: 53-64.
27. Krauel K, Weber C, Brandt S, et al. Platelet factor 4 binding to lipid A of Gramnegative bacteria exposes PF4/heparin-like epitopes. Blood 2012; 120: 3345-3352.
28. Jaax ME, Krauel K, Marschall T, et al. Complex formation with nucleic acids and aptamers alters antigenic properties of platelet factor 4. Blood 2013; 122: 272-281.
29. Lo YM, Zhang J, Leung TN, et al. Rapid clearance of fetal DNA from maternal plasma. Am J Human Genet 1999; 64: 218-224.
30. Krauel K, Potschke C, Weber C, et al. Platelet factor 4 binds to bacteria-inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood 2011; 117: 1370-1378.
31. Krauel K, Furll B, Warkentin TE, et al. Heparin-induced thrombocytopenia--therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes. J Thromb Haemost 2008; 6: 2160-2167.
32. Krauel K, Hackbarth C, Furll B, et al. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood 2012; 119: 1248-1255.
33. Kreimann M, Brandt S, Krauel K, et al. Binding of anti-platelet factor 4/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4. Blood 2014; 124: 2442-2449.
34. Bohm G, Muhr R, Jaenicke R. Quantitative-Analysis of Protein Far Uv Circular-Dichroism Spectra by Neural Networks. Protein Eng 1992; 5: 191-195.
35. Juhl D, Eichler P, Lubenow N, et al. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 2006; 76: 420-426.
36. Wiseman T, Williston S, Brandts JF, et al. Rapid Measurement of Binding Constants and Heats of Binding Using a New Titration Calorimeter. Anal Biochem 1989; 179: 131-137.
37. Freire E, Mayorga OL, Straume M. Isothermal Titration Calorimetry. Anal Chem 1990; 62: A950-A959.
38. Krauel K, Potschke C, Weber C, et al. Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparininduced thrombocytopenia. Blood 2011; 117: 1370-1378.
39. Toumadje A, Alcorn SW, Johnson WC. Extending Cd Spectra of Proteins to 168 Nm Improves the Analysis for Secondary Structures. Anal Biochem 1992; 200: 321-331.
40. Sreerama N, Woody RW. Computation and analysis of protein circular dichroism spectra. Methods Enzymol 2004; 383: 318-351.
41. Greinacher A, Alban S, Dummel V, et al. Characterization of the Structural Requirements for a Carbohydrate-Based Anticoagulant with a Reduced Risk of Inducing the Immunological Type of Heparin-Associated Thrombocytopenia. Thromb Haemost 1995; 74: 886-892.
42. Record MT, Jr., Lohman ML, De Haseth P. Ion effects on ligand-nucleic acid interactions. J Mol Biol 1976; 107: 145-158.
43. Mascotti DP, Lohman TM. Thermodynamics of Single-Stranded Rna-Binding to Oligolysines Containing Tryptophan. Biochem Us 1992; 31: 8932-8946.
44. Sperber BL, Cohen Stuart MA, Schols HA, et al. Overall charge and local charge density of pectin determines the enthalpic and entropic contributions to complexation with beta-lactoglobulin. Biomacromol 2010; 11: 3578-3583.
45. Laugel N, Betscha C, Winterhalter M, et al. Relationship between the growth regime of polyelectrolyte multilayers and the polyanion/polycation complexation enthalpy. J Phys Chem B 2006; 110: 19443-19449.
46. de Souza HKS, Bai GY, Goncalves MP, et al. Whey protein isolate-chitosan interactions: A calorimetric and spectroscopy study. Thermochim Acta 2009; 495: 108-114.
47. Hofs B, Voets IK, de Keizer A, et al. Comparison of complex coacervate core micelles from two diblock copolymers or a single diblock copolymer with a polyelectrolyte. Phys Chem Chem Phys 2006; 8: 4242-4251.
48. Tan WF, Koopal LK, Norde W. Interaction between Humic Acid and Lysozyme, Studied by Dynamic Light Scattering and Isothermal Titration Calorimetry. Environ Sci Technol 2009; 43: 591-596.
49. Girard M, Turgeon SL, Gauthier SF. Quantification of the interactions between beta-lactoglobulin and pectin through capillary electrophoresis analysis. J Agr Food Chem 2003; 51: 6043-6049.
50. Visentin GP, Moghaddam M, Beery SE, et al. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med 2001; 138: 22-31.
51. Leroux D, Canepa S, Viskov C, et al. Binding of heparin-dependent antibodies to PF4 modified by enoxaparin oligosaccharides: evaluation by surface plasmon resonance and serotonin release assay. J Thromb Haemost 2012; 10: 430-436.
52. Whitehead MP, Eagles L, Hooley P, et al. Most bacteria synthesize polyphosphate by unknown mechanisms. Microbiol 2014; 160: 829-831.
53. Arman M, Krauel K, Tilley DO, et al. Amplification of bacteria-induced platelet activation is triggered by FcgammaRIIA, integrin alphaIIbbeta3, and platelet factor 4. Blood 2014; 123: 3166-3174.
54. Greinacher A, Gopinadhan M, Gunther JUG, et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscl Thromb Vasc Biol 2006; 26: 2386-2393.
55. Rauova L, Poncz M, McKenzie SE, et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 2005; 105: 131-138.
56. Qiao S, Luo Q, Zhao Y, et al. Structural basis for lipopolysaccharide insertion in the bacterial outer membrane. Nature 2014; 511: 108-111.
57. Strauss J, Burnham NA, Camesano TA. Atomic force microscopy study of the role of LPS O-antigen on adhesion of E. coli. J Mol Recogn 2009; 22: 347-355.
58. Tan YH, Liu M, Nolting B, et al. A nanoengineering approach for investigation and regulation of protein immobilization. ACS Nano 2008; 2: 2374-2384.
59. Salvaggio HL, Graeber KE, Clarke LE, et al. Mucocutaneous Granulomatous Disease in a Patient With Hermansky-Pudlak Syndrome. J Am Med Assoc Dermatol 2014; 150: 1083-1087.
60. Mora AJ, Wolfsohn DM. The management of gastrointestinal disease in Hermansky-Pudlak syndrome. J Clin Gastroenterol 2011; 45: 700-702.